dog dog

NOW AVAILABLE

VETMEDIN®-CA1 (pimobendan) Chewable Tablets

Early-Stage Treatment for MMVD

Catching myxomatous mitral valve disease (MMVD) early and treating it before it progresses is important to maximize the therapeutic benefit for your dog.

VETMEDIN®-CA1 (pimobendan) 
Chewable Tablets

For dogs in an early stage of myxomatous mitral valve disease (MMVD).

 

It's the medication (conditionally) approved by the FDA to delay the onset of heart failure. 

About VETMEDIN®-CA1 (pimobendan)
Chewable Tablets

VETMEDIN®-CA1 (pimobendan) Chewable Tablets are beef-flavored and half-scored to meet the dosing need of dogs who prefer chews.

It's the only medication (conditionally) approved by the FDA to delay the onset of heart failure.

VETMEDIN®-CA1 Chewable Tablets treat an early stage of the heart disease MMVD to give dogs up to an average of 15.6 more months of symptom-free life.1

Dosage and Administration

VETMEDIN®-CA1 Chewable Tablets should be given to your dog twice a day - morning and at night - approximately 12 hours apart. See your veterinarian as well as full prescribing information for more details.

FAQs

What are the most common heart diseases in dogs?

How do VETMEDIN® Brand Products work?

How long will my dog require treatment with VETMEDIN® Brand Products?

Do VETMEDIN® Brand Products have any side effects?

What should I do if I forget to give a dose of a VETMEDIN® Brand Product?

What should I do if my dog vomits shortly after dosing?

What’s the difference between the VETMEDIN® (pimobendan) brand and a compounded pimobendan?

Vet Discussion Guide

Empower your
conversations with your
vet using our Vet
Discussion Guide.

Image
animals

Education

If your dog has been diagnosed with a heart disease such as congestive heart failure (CHF), myxomatous mitral valve disease (MMVD) or dilated cardiomyopathy (DCM), our education articles will provide you with information about the conditions, common symptoms, treatment options, and resources to help you and your dog navigate this journey.

Important Safety Information

VETMEDIN® (pimobendan) Chewable Tablets and VETMEDIN® Solution (pimobendan oral solution) are for use only in dogs with clinical evidence of heart failure. The most common side effects reported in field studies were poor appetite, lethargy, diarrhea, dyspnea, azotemia, weakness, and ataxia. VETMEDIN® should not be given in case of hypertrophic cardiomyopathy, aortic stenosis, or any other clinical condition where an augmentation of cardiac output is inappropriate for functional or anatomical reasons. 
For more information, please see full prescribing information for Solution or full prescribing information for Chewable Tablets.

VETMEDIN®-CA1 (pimobendan) are for use only in dogs with preclinical MMVD that have a moderate or loud mitral murmur due to mitral regurgitation and cardiomegaly (Stage B2 MMVD, 2019 ACVIM Consensus Statement1). VETMEDIN®-CA1 is conditionally approved by FDA pending a full demonstration of effectiveness under application number 141-556. A diagnosis of MMVD should be made by means of a comprehensive physical and cardiac examination, which should include radiography and echocardiography. The most common side effects seen in dogs with Stage B2 MMVD while taking VETMEDIN®-CA1 Chewable Tablets are cough, vomiting, diarrhea, lethargy and localized pain (such as in the neck or legs). Adverse reactions not related to disease progression in dogs receiving VETMEDIN®-CA1 included diarrhea, vomiting, pain, lameness, arthritis, urinary tract infection, and seizure.

For more information, please refer to the package insert.